News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Eli Lilly's Phase 3 trial shows retatrutide 12 mg delivered an average 28.3% body-weight reduction in the 80-week TRIUMPH-1 study.
  • Rising jet-fuel costs tied to the Middle East conflict are causing airlines to delay aircraft option exercises and raising insolvency risks, IATA and Embraer warn.
  • The U.S. is considering using frozen Iranian assets to fund Gulf infrastructure rebuilding after recent regional conflict.
  • Large credit managers are buying AI-linked debt structured to withstand potential credit strain from heavy corporate AI and data-center investment.
  • Southwest outlines product and network changes ahead of the 737 MAX 7's expected 2027 entry, including Starlink Wi‑Fi and upgraded premium seating.
  • White House AI adviser Sriram Krishnan will step down at the end of June and transition to an outside advisory role.

Latest Articles

Redemptions at Cliffwater Send Shockwaves Through Alternative-asset Stocks

Redemptions at Cliffwater Send Shockwaves Through Alternative-asset Stocks

Shares of large alternative asset managers tumbled after Cliffwater's $31 billion non-traded business development company reported 17% redemption requests in its May 2-29 tender window, up from 14% in February. The fund kept its 5% redemption threshold and said it has liquidity to meet those thresholds for about 12 months. Analysts warn the sector'…

Palvella Therapeutics Announces Completion of FDA Pre-NDA Meeting for QTORIN™ Rapamycin in Microcystic Lymphatic Malformations

Palvella Therapeutics Announces Completion of FDA Pre-NDA Meeting for QTORIN™ Rapamycin in Microcystic Lymphatic Malformations

Palvella Therapeutics has completed a pre-New Drug Application meeting with the FDA for its investigational drug QTORIN™ rapamycin, aimed at treating microcystic lymphatic malformations, a serious and chronic vascular malformation with no current FDA-approved treatment. The company remains on track to submit its NDA in the second half of 2026 and p…

TG Therapeutics Announces Positive Results from Phase 1 Trial Evaluating Subcutaneous BRIUMVI® (ublituximab-xiiy)

TG Therapeutics Announces Positive Results from Phase 1 Trial Evaluating Subcutaneous BRIUMVI® (ublituximab-xiiy)

TG Therapeutics announced favorable Phase 1 trial results for their high-concentration subcutaneous formulation of BRIUMVI (ublituximab-xiiy), showing good tolerability, sustained drug exposure, and comparable biological activity versus intravenous administration. The data bolster confidence in the ongoing Phase 3 trial evaluating quarterly subcuta…

Dyne Therapeutics Announces Completion of Enrollment in Registrational Expansion Cohort of ACHIEVE Trial of Z-Basivarsen for Myotonic Dystrophy Type 1 (DM1)

Dyne Therapeutics Announces Completion of Enrollment in Registrational Expansion Cohort of ACHIEVE Trial of Z-Basivarsen for Myotonic Dystrophy Type 1 (DM1)

Dyne Therapeutics has completed enrollment of 71 participants in the registrational expansion cohort of its Phase 1/2 ACHIEVE trial evaluating z-basivarsen (DYNE-101) for treatment of myotonic dystrophy type 1 (DM1). Topline data are anticipated in Q1 2027, supporting a potential U.S. Accelerated Approval submission by Q3 2027 and possible launch i…

Biogen Announces Upcoming Kidney Presentations at European Renal Association and American Transplant Congresses

Biogen Announces Upcoming Kidney Presentations at European Renal Association and American Transplant Congresses

Biogen announced presentations of 14 abstracts highlighting clinical data from its nephrology portfolio, including approved drug EMPAVELI (pegcetacoplan) and the investigational anti-CD38 antibody felzartamab, at the European Renal Association and American Transplant Congresses. The data show sustained efficacy and safety in treating rare kidney di…

BOJ Flags Potential June Rate Rise as Inflation Risks Mount

BOJ Flags Potential June Rate Rise as Inflation Risks Mount

Bank of Japan Governor Kazuo Ueda signaled the central bank may raise interest rates at its June 15-16 policy meeting if upside risks to inflation prove larger than the economic headwinds from the Middle East conflict. Traders are pricing in an 85% chance of a quarter-point hike, which would take the benchmark rate to its highest level since 1995. …

Trump Says Vance-Rubio Ticket Would Be Tough to Beat in 2028 Speculation

Trump Says Vance-Rubio Ticket Would Be Tough to Beat in 2028 Speculation

In a podcast interview aired Wednesday, President Donald Trump said a hypothetical 2028 ticket featuring Vice President JD Vance and Secretary of State Marco Rubio would be nearly unbeatable. Both men, viewed as potential contenders for the Republican nomination, have appeared at White House briefings defending the administration on issues includin…

Trump Praises Vance-Rubio Pairing as a Potent 2028 Ticket

Trump Praises Vance-Rubio Pairing as a Potent 2028 Ticket

President Donald Trump told a podcast audience that he believes Vice President JD Vance and Secretary of State Marco Rubio would make a formidable Republican ticket in 2028, praising their rapport and suggesting the partnership would be hard to beat. Both officials are viewed as possible contenders for the GOP nomination, though each has downplayed…

DeepSeek Nears 50 Billion Yuan Round as Tencent Leads Major Investment

DeepSeek Nears 50 Billion Yuan Round as Tencent Leads Major Investment

DeepSeek is closing a 50 billion yuan ($7.4 billion) funding round that counts Tencent and Contemporary Amperex among its largest investors, with the company’s founder also making a significant personal contribution. Management has told investors the priority will remain AI research rather than near-term commercialization as the startup expands int…

Cross-Border Strikes Continue as Israel Reports Interception of Hostile Aircraft

Cross-Border Strikes Continue as Israel Reports Interception of Hostile Aircraft

Israeli drone strikes in southern Lebanon killed at least six people and a vehicle was struck just south of Beirut, Lebanese authorities said. Israel reported intercepting a hostile aircraft that crossed from Lebanon into northern Israel, which its military said was most likely a Hezbollah-launched drone. These incidents occurred despite a U.S.-med…

Stray Military Drones Trigger Alarms Along NATO’s Northern Flank

Stray Military Drones Trigger Alarms Along NATO’s Northern Flank

Since late March, numerous military drones believed to be Ukrainian have entered or crashed in Finland, Estonia, Latvia and Lithuania after operations targeting Russian Baltic Sea facilities. The incidents have prompted airspace warnings, the deployment of NATO fighters, civil sheltering measures and the collapse of Latvia's coalition government wh…

Cuba's Daily Endurance: How Residents Keep Going Under Sanctions and a Fuel Blockade

Cuba's Daily Endurance: How Residents Keep Going Under Sanctions and a Fuel Blockade

Cubans across the island are coping with a deepening crisis after a U.S. campaign of tightened sanctions and a fuel blockade. Longstanding shortages and rationing have intensified, forcing creative local responses while fears of reprisals and a frayed public health system limit open protest. Despite severe hardship, the government remains firmly in…

Goldman Flags AI Risks as it Initiates Wolters Kluwer at Neutral

Goldman Flags AI Risks as it Initiates Wolters Kluwer at Neutral

Goldman Sachs began coverage of Wolters Kluwer with a Neutral rating and a €71 price target, describing the Dutch information services group as attractively valued but lacking near-term drivers for a material re-rating. The bank expects Wolters Kluwer to deliver steady EPS compound growth while flagging AI-related threats to key product pricing and…

Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Symptoms

Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Symptoms

Tenaya Therapeutics announced encouraging interim data from its MyPEAK-1 Phase 1b/2 clinical trial evaluating TN-201 gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM). The treatment showed consistent improvements in cardiac remodeling, reduction of left ventricular hypertrophy, symptom relief, and increased exercise capacity acro…